ADMA Biologics, Inc.
HealthcareNASDAQ:ADMA · NASDAQ Global Market
-$0.11 today
Vol 2.99M · Avg 7.02M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$509.9M of revenue converted into $165.4M of net income for the selected period. Gross margin is 61.5% and net margin is 32.6%, showing how much revenue survives after costs and taxes. EPS is $0.68, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $510.2M +19.6% | $426.5M +65.2% | $258.2M +67.6% | $154.1M +90.4% | $80.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $217.4M +5.1% | $206.9M +22.2% | $169.3M +42.5% | $118.8M +48.9% | $79.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $292.8M +33.3% | $219.6M +146.8% | $88.9M +152.2% | $35.3M +2906.4% | $1.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 57.4% +5.9pp | 51.5% +17.0pp | 34.4% +11.6pp | 22.9% +21.4pp | 1.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $4.8M +162.7% | $1.8M -45.1% | $3.3M -8.7% | $3.6M -0.9% | $3.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $91.6M +23.5% | $74.1M +25.6% | $59.0M +12.5% | $52.5M +22.3% | $42.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $101.3M +25.8% | $80.6M +19.7% | $67.3M -9.8% | $74.6M +25.3% | $59.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $8.1M +0.6% | $8.0M -3.4% | $8.3M +17.1% | $7.1M +29.4% | $5.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $197.9M +34.0% | $147.7M +2784.6% | $5.1M +113.0% | -$39.5M +25.6% | -$53.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 38.8% +4.2pp | 34.6% +32.6pp | 2.0% +27.6pp | -25.6% +40.0pp | -65.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | $191.4M +37.7% | $139.0M +542.5% | $21.6M +155.0% | -$39.4M +32.6% | -$58.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 37.5% +4.9pp | 32.6% +24.2pp | 8.4% +33.9pp | -25.5% +46.6pp | -72.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.9M -10.8% | $2.1M +29.7% | $1.6M +3506.7% | $44.8K +29.8% | $34.5K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $7.1M -49.0% | $13.9M -44.3% | $25.0M +29.8% | $19.3M +47.7% | $13.1M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$8.8M +33.8% | -$13.3M +73.4% | -$49.9M -87.9% | -$26.5M -99.9% | -$13.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $182.7M +45.3% | $125.7M +545.2% | -$28.2M +57.2% | -$65.9M +8.0% | -$71.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 35.8% +6.3pp | 29.5% +40.4pp | -10.9% +31.8pp | -42.8% +45.7pp | -88.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $35.7M +149.6% | -$72.0M | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $146.9M -25.7% | $197.7M +800.0% | -$28.2M +57.2% | -$65.9M +8.0% | -$71.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 28.8% -17.6pp | 46.4% +57.3pp | -10.9% +31.8pp | -42.8% +45.7pp | -88.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 -27.1% | $1 +753.8% | -$0 +69.8% | -$0 +29.5% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 -25.9% | $1 +723.1% | -$0 +69.8% | -$0 +29.5% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $238.3M +2.2% | $233.1M +4.1% | $224.0M +13.2% | $197.9M +41.8% | $139.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $244.9M +0.6% | $243.3M +8.6% | $224.0M +13.2% | $197.9M +41.8% | $139.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Belite Bio, Inc
NASDAQ:BLTE
$5.54B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.12B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$4.99B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
Telix Pharmaceuticals Limited
NASDAQ:TLX
$3.24B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ADMA generate?
ADMA Biologics, Inc. (ADMA) reported $510.17M of revenue in fiscal 2025.
Is ADMA profitable?
ADMA Biologics, Inc. (ADMA) reported $146.93M of net income, with a net margin of 28.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.